International Stem Cell Corp. (ISCO) Posts Q3, FH13 Sales Increase – Reflects Strength in Subsidiary Contributions
International Stem Cell Corp., a biotech company developing novel stem cell-based therapies and biomedical products, today announced financial results for the three and six months ended June 30, 2013. Revenue for the quarter increased 38 percent to $1.46 million, compared to revenues of $1.06 million for the same period in 2012. Sales for the company’s Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT) increased by 36 percent and 40 percent, respectively; LSC and LCT accounted for 49 percent and 51 percent of total revenue, respectively. ISCO’s marketing expenses for the quarter increased 24 percent $0.68 million, reflecting higher spending…